RT Journal Article
T1 Salvage Therapy with CeftolozaneTazobactam for Multidrug-Resistant Pseudomonas aeruginosa Infections
A1 Jose Caston, Juan
A1 De la Torre, Alvaro
A1 Ruiz-Camps, Isabel
A1 Luisa Sorli, Maria
A1 Torres, Vicente
A1 Torre-Cisneros, Julian
K1 Pseudomonas aeruginosa
K1 Salvage therapy
K1 Ceftolozane-tazobactam
AB Infections caused by multidrug-resistant Pseudomonas aeruginosa (MDRPA) present a major problem for therapeutic management. We report here our experience with 12 patients with a severe MDRPA infection (6 of which were pneumonia) who received salvage therapy with ceftolozane-tazobactam after inappropriate empirical treatment and/or suboptimal targeted treatment. Although 10 of the 12 patients (83.3%) experienced septic shock, only 3 patients (25%) died during the follow-up period. Microbiological cure in 7 patients (58.3%) was observed.
PB American Society for Microbiology
SN 0066-4804
YR 2016
FD 2016-12-08
LK http://hdl.handle.net/10668/19011
UL http://hdl.handle.net/10668/19011
LA en
NO Castón JJ, De la Torre Á, Ruiz-Camps I, Sorlí ML, Torres V, Torre-Cisneros J. Salvage Therapy with Ceftolozane-Tazobactam for Multidrug-Resistant Pseudomonas aeruginosa Infections. Antimicrob Agents Chemother. 2017 Feb 23;61(3):e02136-16
DS RISalud
RD Apr 3, 2025